Keilholz U, Menssen H D, Gaiger A, Menke A, Oji Y, Oka Y, Scheibenbogen C, Stauss H, Thiel E, Sugiyama H
Department of Medicine III, Charité, Campus Benjamin Franklin, Berlin, Germany.
Leukemia. 2005 Aug;19(8):1318-23. doi: 10.1038/sj.leu.2403817.
The transcription factor Wilms' tumour gene 1 (WT1) is important as a prognostic marker as well as in the detection and monitoring of minimal residual disease in leukaemia and myelodysplastic syndromes. Evidence has accumulated over the past decade to show that WT1 is a key molecule for tumour proliferation in a large number of human neoplasms most prominent in acute leukaemias, making it a suitable target for therapeutic strategies. Based on animal results, showing safety and efficacy of immunization with WT1 peptides and protein, early clinical trials in leukaemia have recently been initiated. The First International Conference on WT1 in Human Neoplasia was held in Berlin, March 11--12, 2004. This report reviews the current knowledge on the role of WT1 in tumour promotion and as a diagnostic and therapeutic target, and summarizes the data presented and discussed in this meeting.
转录因子肾母细胞瘤基因1（WT1）作为一种预后标志物，以及在白血病和骨髓增生异常综合征微小残留病的检测与监测中都具有重要意义。在过去十年中，已有越来越多的证据表明，WT1是大量人类肿瘤（在急性白血病中最为突出）肿瘤增殖的关键分子，使其成为治疗策略的一个合适靶点。基于动物实验结果显示WT1肽和蛋白免疫的安全性和有效性，最近已启动白血病的早期临床试验。2004年3月11日至12日，第一届人类肿瘤WT1国际会议在柏林召开。本报告回顾了目前关于WT1在肿瘤促进中的作用以及作为诊断和治疗靶点的知识，并总结了本次会议上展示和讨论的数据。
